1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. XENON PHARMACEUTICALS INC

Xenon Pharmaceuticals Inc

XNAS: XENE

Download real time

35.17 -0.43 (-1.21%)

52W Low on Feb 28, 2025

372.8K XNAS Volume

XNAS 18 Mar, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share
6S
17W
6O
0T
2,692

Market Cap

High in industry
-11.5

PE TTM

Negative PE TTM
0.4

PEG TTM

PEG TTM is less than 1
3.6

Price to Book

Below industry Median
0.1

Beta 1Year

Very Low volatility
Board Meeting
The board meeting for Xenon Pharmaceuticals Inc is scheduled for today, for the purpose of Stifel 2025 Virtual CNS Forum See details


Insider Trading disclosures for Xenon Pharmaceuticals Inc

The latest disclosure was made by Ian C. Mortimer in Xenon Pharmaceuticals Inc where a trade of 275,000 Share Option (Right to Buy) done was reported to US exchanges on March 12, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Ian C. Mortimer Director, PRESIDENT & CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Mar 2025 275,000 275,000 - - Share Option (Right to Buy)
Ian C. Mortimer Director, PRESIDENT & CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Mar 2025 50,000 50,000 - - Restricted Share Units
Andrea DiFabio Chief Legal Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Mar 2025 80,000 80,000 - - Share Option (Right to Buy)
Andrea DiFabio Chief Legal Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Mar 2025 15,000 15,000 - - Restricted Share Units
Christopher John Kenney Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Mar 2025 80,000 80,000 - - Share Option (Right to Buy)
Christopher John Kenney Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Mar 2025 15,000 15,000 - - Restricted Share Units
Ian C. Mortimer Director, PRESIDENT & CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.76 per share. 23 Jan 2025 16,217 47,519 (0%) 0% 17.8 288,014 Common Shares
Ian C. Mortimer Director, PRESIDENT & CEO Sale of securities on an exchange or to another person at price $ 40.08 per share. 23 Jan 2025 16,217 31,302 (0%) 0% 40.1 649,977 Common Shares
Ian C. Mortimer Director, PRESIDENT & CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.76 per share. 23 Jan 2025 22,468 53,770 (0%) 0% 17.8 399,032 Common Shares
Ian C. Mortimer Director, PRESIDENT & CEO Sale of securities on an exchange or to another person at price $ 40.20 per share. 23 Jan 2025 22,468 31,302 (0%) 0% 40.2 903,214 Common Shares
Ian C. Mortimer Director, PRESIDENT & CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.76 per share. 23 Jan 2025 15,166 46,468 (0%) 0% 17.8 269,348 Common Shares
Ian C. Mortimer Director, PRESIDENT & CEO Sale of securities on an exchange or to another person at price $ 40.46 per share. 23 Jan 2025 15,166 31,302 (0%) 0% 40.5 613,616 Common Shares
Ian C. Mortimer Director, PRESIDENT & CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.76 per share. 23 Jan 2025 1,149 32,451 (0%) 0% 17.8 20,406 Common Shares
Ian C. Mortimer Director, PRESIDENT & CEO Sale of securities on an exchange or to another person at price $ 41.07 per share. 23 Jan 2025 1,149 31,302 (0%) 0% 41.1 47,189 Common Shares
Ian C. Mortimer Director, PRESIDENT & CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 23 Jan 2025 16,217 38,783 - - Stock Option (Right to Buy)
Ian C. Mortimer Director, PRESIDENT & CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 23 Jan 2025 22,468 16,315 - - Stock Option (Right to Buy)
Ian C. Mortimer Director, PRESIDENT & CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 23 Jan 2025 16,315 0 - - Stock Option (Right to Buy)
Sherry Aulin Chief Financial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.44 per share. 18 Dec 2024 9,334 9,334 (0%) 0% 9.4 88,113 Common Shares
Aulin Sherry Chief Financial Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.28 per share. 18 Dec 2024 4,490 11,510 (0%) 0% 41.3 185,347 Common Shares
Sherry Aulin Chief Financial Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.28 per share. 18 Dec 2024 2,135 7,199 (0%) 0% 41.3 88,133 Common Shares
Aulin Sherry Chief Financial Officer Sale of securities on an exchange or to another person at price $ 41.23 per share. 18 Dec 2024 7,199 0 (0%) 0% 41.2 296,815 Common Shares
Sherry Aulin Chief Financial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 18 Dec 2024 16,000 6,000 - - Stock Option (Right to Buy)
Aulin Sherry Chief Financial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 18 Dec 2024 9,334 0 - - Stock Option (Right to Buy)
Aulin Sherry Chief Financial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.58 per share. 18 Dec 2024 16,000 16,000 (0%) 0% 11.6 185,280 Common Shares
Aulin Sherry Chief Financial Officer Sale of securities on an exchange or to another person at price $ 41.19 per share. 18 Dec 2024 11,510 0 (0%) 0% 41.2 474,097 Common Shares
Gary Patou Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.38 per share. 22 Nov 2024 3,500 27,073 (0%) 0% 7.4 25,830 Common Shares
Gary Patou Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 22 Nov 2024 3,086 0 - - Stock Option (Right to Buy)
Gary Patou Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 22 Nov 2024 3,500 0 - - Stock Option (Right to Buy)
Gary Patou Director Sale of securities on an exchange or to another person at price $ 41.05 per share. 22 Nov 2024 2,040 23,573 (0%) 0% 41.1 83,742 Common Shares
Gary Patou Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.80 per share. 22 Nov 2024 1,046 25,613 (0%) 0% 39.8 41,631 Common Shares
Gary Patou Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.48 per share. 22 Nov 2024 3,086 26,659 (0%) 0% 13.5 41,599 Common Shares
Gary Patou Director Sale of securities on an exchange or to another person at price $ 41.11 per share. 22 Nov 2024 2,851 23,573 (0%) 0% 41.1 117,205 Common Shares
Gary Patou Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.80 per share. 22 Nov 2024 649 26,424 (0%) 0% 39.8 25,830 Common Shares
Patrick C. Machado Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Jun 2024 15,542 15,542 - - Stock Option (Right to Buy)
Gary Patou Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Jun 2024 15,542 15,542 - - Stock Option (Right to Buy)
Justin David Gover Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Jun 2024 15,542 15,542 - - Stock Option (Right to Buy)
Dawn A. Svoronos Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Jun 2024 15,542 15,542 - - Stock Option (Right to Buy)
Steven Gannon Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Jun 2024 15,542 15,542 - - Stock Option (Right to Buy)
Elizabeth A. Garofalo Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Jun 2024 15,542 15,542 - - Stock Option (Right to Buy)
Gillian M. Cannon Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Jun 2024 15,542 15,542 - - Stock Option (Right to Buy)
Ian C. Mortimer Director, PRESIDENT & CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Mar 2024 250,000 250,000 - - Stock Option (Right to Buy)
Robin Sherrington EVP, Strategy & Innovation Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Mar 2024 65,000 65,000 - - Stock Option (Right to Buy)
James R. Empfield EVP, Drug Discovery Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Mar 2024 65,000 65,000 - - Stock Option (Right to Buy)
Andrea DiFabio Chief Legal Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Mar 2024 100,000 100,000 - - Stock Option (Right to Buy)
Seggern Christopher Von Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Mar 2024 100,000 100,000 - - Stock Option (Right to Buy)
Sherry Aulin Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Mar 2024 100,000 100,000 - - Stock Option (Right to Buy)
Christopher John Kenney Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Mar 2024 100,000 100,000 - - Stock Option (Right to Buy)
Elizabeth A. Garofalo Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.56 per share. 08 Mar 2024 3,500 3,500 (0%) 0% 18.6 64,960 Common Shares
Elizabeth A. Garofalo Director Sale of securities on an exchange or to another person at price $ 45.69 per share. 08 Mar 2024 2,092 0 (0%) 0% 45.7 95,583 Common Shares
Elizabeth A. Garofalo Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.16 per share. 08 Mar 2024 1,408 2,092 (0%) 0% 46.2 64,993 Common Shares
Elizabeth A. Garofalo Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 08 Mar 2024 3,500 16,500 - - Stock Option (Right to Buy)
Robin Sherrington EVP, Strategy & Innovation Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 07 Mar 2024 7,407 0 - - Stock Option (Right to Buy)
Robin Sherrington EVP, Strategy & Innovation Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.96 per share. 07 Mar 2024 1,289 15,535 (0%) 0% 46.0 59,242 Common Shares
Robin Sherrington EVP, Strategy & Innovation Sale of securities on an exchange or to another person at price $ 46.15 per share. 07 Mar 2024 1,019 14,516 (0%) 0% 46.2 47,027 Common Shares
Robin Sherrington EVP, Strategy & Innovation Sale of securities on an exchange or to another person at price $ 46.30 per share. 07 Mar 2024 6,118 8,398 (0%) 0% 46.3 283,263 Common Shares
Robin Sherrington EVP, Strategy & Innovation Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 07 Mar 2024 1,234 0 - - Stock Option (Right to Buy)
Robin Sherrington EVP, Strategy & Innovation Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.85 per share. 07 Mar 2024 1,234 9,632 (0%) 0% 9.9 12,155 Common Shares
Robin Sherrington EVP, Strategy & Innovation Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.96 per share. 07 Mar 2024 215 9,417 (0%) 0% 46.0 9,881 Common Shares
Robin Sherrington EVP, Strategy & Innovation Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.85 per share. 07 Mar 2024 7,407 16,824 (0%) 0% 9.9 72,959 Common Shares
Steven Gannon Director Sale of securities on an exchange or to another person at price $ 46.25 per share. 07 Mar 2024 5,000 9,000 (0%) 0% 46.3 231,250 Common Shares
Steven Gannon Director Sale of securities on an exchange or to another person at price $ 46.30 per share. 07 Mar 2024 5,000 4,000 (0%) 0% 46.3 231,513 Common Shares
Steven Gannon Director Sale of securities on an exchange or to another person at price $ 46.20 per share. 07 Mar 2024 2,000 2,000 (0%) 0% 46.2 92,402 Common Shares
Steven Gannon Director Sale of securities on an exchange or to another person at price $ 46.45 per share. 07 Mar 2024 1,000 14,000 (0%) 0% 46.5 46,450 Common Shares
Robin Sherrington EVP, Strategy & Innovation Other type of transaction at price $ 0.00 per share. 29 Dec 2023 8,398 8,398 (0%) 0% 0 Common Shares
Mohammad Azab Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Dec 2023 823 0 - - Stock Option (Right to Buy)
Mohammad Azab Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Dec 2023 3,497 0 - - Stock Option (Right to Buy)
Azab Mohammad Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.85 per share. 19 Dec 2023 3,497 74,225 (0%) 0% 9.8 34,445 Common Shares
Azab Mohammad Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.85 per share. 19 Dec 2023 823 70,728 (0%) 0% 9.9 8,107 Common Shares
Gary Patou Director Sale of securities on an exchange or to another person at price $ 41.05 per share. 13 Dec 2023 7,598 4,902 (0%) 0% 41.1 311,898 Common Shares
Dawn A. Svoronos Director Sale of securities on an exchange or to another person at price $ 38.70 per share. 24 Aug 2023 25,000 25,000 (0%) 0% 38.7 967,500 Common Shares
Justin David Gover Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Aug 2023 28,000 28,000 - - Stock Option (Right to Buy)
Gillian M. Cannon Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Aug 2023 28,000 28,000 - - Stock Option (Right to Buy)
Patrick C. Machado Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2023 18,475 18,475 - - Stock Option (Right to Buy)
Mohammad Azab Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2023 18,475 18,475 - - Stock Option (Right to Buy)
Gary Patou Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2023 18,475 18,475 - - Stock Option (Right to Buy)
Dawn A. Svoronos Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2023 18,475 18,475 - - Stock Option (Right to Buy)
Simon Pimstone Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2023 18,475 18,475 - - Stock Option (Right to Buy)
Steven Gannon Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2023 18,475 18,475 - - Stock Option (Right to Buy)
Elizabeth A. Garofalo Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2023 18,475 18,475 - - Stock Option (Right to Buy)
Simon Pimstone Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.69 per share. 30 May 2023 9,318 15,318 (0%) 0% 7.7 71,655 Common Shares
Simon Pimstone Director Sale of securities on an exchange or to another person at price $ 38.63 per share. 30 May 2023 18,006 37,000 (0%) 0% 38.6 695,572 Common Shares
Simon Pimstone Director Sale of securities on an exchange or to another person at price $ 39.90 per share. 30 May 2023 19,000 18,000 (0%) 0% 39.9 758,100 Common Shares
Simon Pimstone Director Sale of securities on an exchange or to another person at price $ 38.53 per share. 30 May 2023 12,000 6,000 (0%) 0% 38.5 462,360 Common Shares
Simon Pimstone Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.85 per share. 30 May 2023 29,835 35,835 (0%) 0% 9.9 293,875 Common Shares
Simon Pimstone Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.37 per share. 30 May 2023 6,165 29,670 (0%) 0% 38.4 236,551 Common Shares
Simon Pimstone Director Sale of securities on an exchange or to another person at price $ 38.81 per share. 30 May 2023 23,670 6,000 (0%) 0% 38.8 918,633 Common Shares
Simon Pimstone Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.76 per share. 30 May 2023 50,000 56,000 (0%) 0% 17.8 888,000 Common Shares
Simon Pimstone Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.37 per share. 30 May 2023 23,144 32,856 (0%) 0% 38.4 888,035 Common Shares
Simon Pimstone Director Sale of securities on an exchange or to another person at price $ 38.69 per share. 30 May 2023 26,856 6,000 (0%) 0% 38.7 1,039,059 Common Shares
Simon Pimstone Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.53 per share. 30 May 2023 1,860 13,458 (0%) 0% 38.5 71,666 Common Shares
Simon Pimstone Director Sale of securities on an exchange or to another person at price $ 38.97 per share. 30 May 2023 7,458 6,000 (0%) 0% 39.0 290,638 Common Shares
Simon Pimstone Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.76 per share. 30 May 2023 45,000 51,000 (0%) 0% 17.8 799,200 Common Shares
Simon Pimstone Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.53 per share. 30 May 2023 20,745 30,255 (0%) 0% 38.5 799,305 Common Shares
Simon Pimstone Director Sale of securities on an exchange or to another person at price $ 38.78 per share. 30 May 2023 24,255 6,000 (0%) 0% 38.8 940,609 Common Shares
Simon Pimstone Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 30 May 2023 29,835 0 - - Stock Option (Right to Buy)
Simon Pimstone Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 30 May 2023 50,000 45,000 - - Stock Option (Right to Buy)
Simon Pimstone Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 30 May 2023 9,318 30,682 - - Stock Option (Right to Buy)
Simon Pimstone Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 30 May 2023 45,000 0 - - Stock Option (Right to Buy)
Ian C. Mortimer Director, PRESIDENT & CEO Sale of securities on an exchange or to another person at price $ 41.44 per share. 24 May 2023 17,069 24,213 (0%) 0% 41.4 707,339 Common Shares
Ian C. Mortimer Director, PRESIDENT & CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 24 May 2023 6,172 0 - - Stock Option (Right to Buy)
Ian C. Mortimer Director, PRESIDENT & CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 24 May 2023 20,576 0 - - Stock Option (Right to Buy)
Ian C. Mortimer Director, PRESIDENT & CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.84 per share. 24 May 2023 7,310 41,282 (0%) 0% 41.8 305,850 Common Shares
Ian C. Mortimer Director, PRESIDENT & CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.85 per share. 24 May 2023 20,576 44,789 (0%) 0% 9.9 202,674 Common Shares
Ian C. Mortimer Director, PRESIDENT & CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 24 May 2023 42,592 0 - - Stock Option (Right to Buy)
Ian C. Mortimer Director, PRESIDENT & CEO Sale of securities on an exchange or to another person at price $ 41.49 per share. 24 May 2023 1,407 31,302 (0%) 0% 41.5 58,376 Common Shares
Ian C. Mortimer Director, PRESIDENT & CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.84 per share. 24 May 2023 1,171 32,709 (0%) 0% 41.8 48,995 Common Shares
Ian C. Mortimer Director, PRESIDENT & CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.85 per share. 24 May 2023 6,172 33,880 (0%) 0% 9.8 60,794 Common Shares
Ian C. Mortimer Director, PRESIDENT & CEO Sale of securities on an exchange or to another person at price $ 41.37 per share. 24 May 2023 13,179 27,708 (0%) 0% 41.4 545,215 Common Shares
Ian C. Mortimer Director, PRESIDENT & CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.84 per share. 24 May 2023 3,902 40,887 (0%) 0% 41.8 163,260 Common Shares
Ian C. Mortimer Director, PRESIDENT & CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.44 per share. 24 May 2023 42,592 48,592 (0%) 0% 9.4 402,068 Common Shares
Christopher John Kenney Chief Medical Officer Sale of securities on an exchange or to another person at price $ 35.01 per share. 24 Mar 2023 700 0 (0%) 0% 35.0 24,507 Common Shares
Ian C. Mortimer Director, PRESIDENT & CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Mar 2023 380,000 380,000 - - Stock Option (Right to Buy)
Robin Sherrington EVP, Strategy & Innovation Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Mar 2023 75,000 75,000 - - Stock Option (Right to Buy)
James R. Empfield EVP, Drug Discovery Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Mar 2023 75,000 75,000 - - Stock Option (Right to Buy)
Andrea DiFabio Chief Legal Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Mar 2023 45,000 45,000 - - Stock Option (Right to Buy)
Seggern Christopher Von Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Mar 2023 90,000 90,000 - - Stock Option (Right to Buy)
Sherry Aulin Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Mar 2023 120,000 120,000 - - Stock Option (Right to Buy)
Christopher John Kenney Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Mar 2023 120,000 120,000 - - Stock Option (Right to Buy)
Simon Pimstone Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.59 per share. 07 Mar 2023 30,864 64,866 (0%) 0% 2.6 79,938 Common Shares
Simon Pimstone Director Sale of securities on an exchange or to another person at price $ 37.01 per share. 07 Mar 2023 10,990 34,002 (0%) 0% 37.0 406,740 Common Shares
Simon Pimstone Director Sale of securities on an exchange or to another person at price $ 36.94 per share. 07 Mar 2023 8,242 55,006 (0%) 0% 36.9 304,459 Common Shares
Simon Pimstone Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.13 per share. 07 Mar 2023 2,160 44,992 (0%) 0% 37.1 80,201 Common Shares
Simon Pimstone Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 07 Mar 2023 41,152 0 - - Stock Option (Right to Buy)
Simon Pimstone Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 07 Mar 2023 30,864 0 - - Stock Option (Right to Buy)
Simon Pimstone Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.68 per share. 07 Mar 2023 41,152 47,152 (0%) 0% 2.7 110,287 Common Shares
Simon Pimstone Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.13 per share. 07 Mar 2023 1,618 63,248 (0%) 0% 37.1 60,076 Common Shares
Mohammad Azab Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.68 per share. 12 Dec 2022 3,086 69,905 (0%) 0% 2.7 8,270 Common Shares
Mohammad Azab Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 12 Dec 2022 3,086 0 - - Stock Option (Right to Buy)
Gary Patou Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.37 per share. 23 Nov 2022 120 25,510 (0%) 0% 34.4 4,124 Common Shares
Gary Patou Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.68 per share. 23 Nov 2022 2,057 25,630 (0%) 0% 2.7 5,513 Common Shares
Gary Patou Director Sale of securities on an exchange or to another person at price $ 34.33 per share. 23 Nov 2022 2,057 23,573 (0%) 0% 34.3 70,610 Common Shares
Gary Patou Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 23 Nov 2022 2,057 0 - - Stock Option (Right to Buy)
Gary Patou Director Sale of securities on an exchange or to another person at price $ 34.79 per share. 23 Nov 2022 1,937 23,573 (0%) 0% 34.8 67,390 Common Shares
Sherry Aulin Chief Financial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.75 per share. 02 Sep 2022 6,511 18,648 (0%) 0% 4.7 30,927 Common Shares
Sherry Aulin Chief Financial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.10 per share. 02 Sep 2022 2,292 12,137 (0%) 0% 3.1 7,105 Common Shares
Sherry Aulin Chief Financial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.40 per share. 02 Sep 2022 813 9,845 (0%) 0% 8.4 6,829 Common Shares
Sherry Aulin Chief Financial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.44 per share. 02 Sep 2022 9,000 9,000 (0%) 0% 9.4 84,960 Common Shares
Sherry Aulin Chief Financial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.50 per share. 02 Sep 2022 32 9,032 (0%) 0% 7.5 240 Common Shares
Sherry Aulin Chief Financial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 02 Sep 2022 6,511 0 - - Stock Option (Right to Buy)
Sherry Aulin Chief Financial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 02 Sep 2022 2,292 0 - - Stock Option (Right to Buy)
Sherry Aulin Chief Financial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 02 Sep 2022 813 0 - - Stock Option (Right to Buy)
Sherry Aulin Chief Financial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 02 Sep 2022 32 0 - - Stock Option (Right to Buy)
Sherry Aulin Chief Financial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 02 Sep 2022 9,000 0 - - Stock Option (Right to Buy)
Sherry Aulin Chief Financial Officer Sale of securities on an exchange or to another person at price $ 39.57 per share. 02 Sep 2022 15,355 0 (0%) 0% 39.6 607,597 Common Shares
Sherry Aulin Chief Financial Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.53 per share. 02 Sep 2022 3,293 15,355 (0%) 0% 39.5 130,172 Common Shares
Robin Sherrington EVP, Strategy & Innovation Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.75 per share. 31 Aug 2022 5,000 39,720 (0%) 0% 4.8 23,750 Common Shares
Robin Sherrington EVP, Strategy & Innovation Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 31 Aug 2022 50,000 0 - - Stock Option (Right to Buy)
Robin Sherrington EVP, Strategy & Innovation Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 31 Aug 2022 5,000 0 - - Stock Options (Right to Buy)
Robin Sherrington EVP, Strategy & Innovation Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 31 Aug 2022 17,488 0 - - Stock Options (Right to Buy)
Robin Sherrington EVP, Strategy & Innovation Sale of securities on an exchange or to another person at price $ 38.80 per share. 31 Aug 2022 8,776 16,796 (0%) 0% 38.8 340,509 Common Shares
Robin Sherrington EVP, Strategy & Innovation Sale of securities on an exchange or to another person at price $ 38.03 per share. 31 Aug 2022 35,103 25,572 (0%) 0% 38.0 1,334,967 Common Shares
Robin Sherrington EVP, Strategy & Innovation Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.81 per share. 31 Aug 2022 6,121 60,675 (0%) 0% 38.8 237,556 Common Shares
Robin Sherrington EVP, Strategy & Innovation Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.75 per share. 31 Aug 2022 50,000 66,796 (0%) 0% 4.8 237,500 Common Shares
Robin Sherrington EVP, Strategy & Innovation Sale of securities on an exchange or to another person at price $ 38.57 per share. 31 Aug 2022 21,352 16,796 (0%) 0% 38.6 823,547 Common Shares
Robin Sherrington EVP, Strategy & Innovation Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.86 per share. 31 Aug 2022 1,572 38,148 (0%) 0% 37.9 59,516 Common Shares
Robin Sherrington EVP, Strategy & Innovation Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.67 per share. 31 Aug 2022 17,488 34,720 (0%) 0% 2.7 46,693 Common Shares
Simon Pimstone Director Sale of securities on an exchange or to another person at price $ 37.76 per share. 12 Aug 2022 33,942 58,058 (0%) 0% 37.8 1,281,650 Common Shares
Simon Pimstone Director Sale of securities on an exchange or to another person at price $ 37.91 per share. 12 Aug 2022 43,135 140,000 (0%) 0% 37.9 1,635,248 Common Shares
Simon Pimstone Director Sale of securities on an exchange or to another person at price $ 38.60 per share. 12 Aug 2022 47,000 93,000 (0%) 0% 38.6 1,814,200 Common Shares
Simon Pimstone Director Sale of securities on an exchange or to another person at price $ 39.15 per share. 12 Aug 2022 1,000 92,000 (0%) 0% 39.2 39,150 Common Shares
Simon Pimstone Director Sale of securities on an exchange or to another person at price $ 38.29 per share. 12 Aug 2022 32,058 26,000 (0%) 0% 38.3 1,227,501 Common Shares
Simon Pimstone Director Sale of securities on an exchange or to another person at price $ 38.87 per share. 12 Aug 2022 20,000 6,000 (0%) 0% 38.9 777,400 Common Shares
James R. Empfield EVP, Drug Discovery Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 12 Aug 2022 20,000 0 - - Stock Option (Right to Buy)
James R. Empfield EVP, Drug Discovery Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 12 Aug 2022 45,000 0 - - Stock Option (Right to Buy)
James R. Empfield EVP, Drug Discovery Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.10 per share. 12 Aug 2022 20,000 30,000 (0%) 0% 3.1 62,000 Common Shares
James R. Empfield EVP, Drug Discovery Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.75 per share. 12 Aug 2022 45,000 75,000 (0%) 0% 4.8 213,750 Common Shares
James R. Empfield EVP, Drug Discovery Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.02 per share. 12 Aug 2022 7,257 67,743 (0%) 0% 38.0 275,911 Common Shares
James R. Empfield EVP, Drug Discovery Sale of securities on an exchange or to another person at price $ 38.08 per share. 12 Aug 2022 35,868 31,875 (0%) 0% 38.1 1,365,853 Common Shares
James R. Empfield EVP, Drug Discovery Sale of securities on an exchange or to another person at price $ 38.68 per share. 12 Aug 2022 21,875 10,000 (0%) 0% 38.7 846,125 Common Shares
Patrick C. Machado Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 28 Jun 2022 18,000 18,000 - - Stock Option (Right to Buy)
Mohammad Azab Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 28 Jun 2022 18,000 18,000 - - Stock Option (Right to Buy)
Gary Patou Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 28 Jun 2022 18,000 18,000 - - Stock Option (Right to Buy)
Dawn A. Svoronos Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 28 Jun 2022 18,000 18,000 - - Stock Option (Right to Buy)
Simon Pimstone Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 28 Jun 2022 18,000 18,000 - - Stock Option (Right to Buy)
Steven Gannon Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 28 Jun 2022 18,000 18,000 - - Stock Option (Right to Buy)
Elizabeth A. Garofalo Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 28 Jun 2022 18,000 18,000 - - Stock Option (Right to Buy)
Ian C. Mortimer Director, PRESIDENT & CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Mar 2022 400,000 400,000 - - Stock Option (Right to Buy)
Simon Pimstone Director, Executive Chair Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Mar 2022 25,000 25,000 - - Stock Option (Right to Buy)
Robin Sherrington EVP, Strategy & Innovation Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Mar 2022 75,000 75,000 - - Stock Option (Right to Buy)
James R. Empfield EVP, Drug Discovery Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Mar 2022 65,000 65,000 - - Stock Option (Right to Buy)
Seggern Christopher Von Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Mar 2022 100,000 100,000 - - Stock Option (Right to Buy)
Sherry Aulin Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Mar 2022 125,000 125,000 - - Stock Option (Right to Buy)
Christopher John Kenney Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Mar 2022 125,000 125,000 - - Stock Option (Right to Buy)
Simon Pimstone Director Sale of securities on an exchange or to another person at price $ 30.80 per share. 04 Mar 2022 2,500 193,135 (0%) 0% 30.8 77,000 Common Shares
Robin Sherrington EVP, Strategy & Innovation Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.42 per share. 04 Mar 2022 696 32,770 (0%) 0% 31.4 21,868 Common Shares
Robin Sherrington EVP, Strategy & Innovation Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 04 Mar 2022 6,172 0 - - Stock Option (Right to Buy)
Robin Sherrington EVP, Strategy & Innovation Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 04 Mar 2022 1,234 0 - - Stock Option (Right to Buy)
Robin Sherrington EVP, Strategy & Innovation Sale of securities on an exchange or to another person at price $ 30.23 per share. 04 Mar 2022 5,000 17,232 (0%) 0% 30.2 151,150 Common Shares
Robin Sherrington EVP, Strategy & Innovation Sale of securities on an exchange or to another person at price $ 31.05 per share. 04 Mar 2022 5,000 22,232 (0%) 0% 31.1 155,250 Common Shares
Robin Sherrington EVP, Strategy & Innovation Sale of securities on an exchange or to another person at price $ 30.15 per share. 04 Mar 2022 5,000 27,232 (0%) 0% 30.2 150,750 Common Shares
Robin Sherrington EVP, Strategy & Innovation Sale of securities on an exchange or to another person at price $ 30.56 per share. 04 Mar 2022 6,710 32,232 (0%) 0% 30.6 205,058 Common Shares
Robin Sherrington EVP, Strategy & Innovation Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.67 per share. 04 Mar 2022 6,172 38,942 (0%) 0% 3.7 22,651 Common Shares
Robin Sherrington EVP, Strategy & Innovation Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.67 per share. 04 Mar 2022 1,234 33,466 (0%) 0% 3.7 4,529 Common Shares
James R. Empfield EVP, Drug Discovery Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.76 per share. 04 Mar 2022 40,000 51,805 (0%) 0% 6.8 270,400 Common Shares
James R. Empfield EVP, Drug Discovery Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.40 per share. 04 Mar 2022 2,500 12,500 (0%) 0% 8.4 21,000 Common Shares
James R. Empfield EVP, Drug Discovery Sale of securities on an exchange or to another person at price $ 30.79 per share. 04 Mar 2022 18,315 10,000 (0%) 0% 30.8 563,919 Common Shares
James R. Empfield EVP, Drug Discovery Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.42 per share. 04 Mar 2022 6,685 28,315 (0%) 0% 31.4 210,043 Common Shares
James R. Empfield EVP, Drug Discovery Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.40 per share. 04 Mar 2022 25,000 35,000 (0%) 0% 8.4 210,000 Common Shares
James R. Empfield EVP, Drug Discovery Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 04 Mar 2022 40,000 0 - - Stock Option (Right to Buy)
James R. Empfield EVP, Drug Discovery Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 04 Mar 2022 2,500 0 - - Stock Option (Right to Buy)
James R. Empfield EVP, Drug Discovery Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 04 Mar 2022 25,000 0 - - Stock Option (Right to Buy)
James R. Empfield EVP, Drug Discovery Sale of securities on an exchange or to another person at price $ 30.54 per share. 04 Mar 2022 31,048 10,000 (0%) 0% 30.5 948,206 Common Shares
James R. Empfield EVP, Drug Discovery Sale of securities on an exchange or to another person at price $ 30.62 per share. 04 Mar 2022 1,805 41,048 (0%) 0% 30.6 55,269 Common Shares
James R. Empfield EVP, Drug Discovery Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.23 per share. 04 Mar 2022 8,952 42,853 (0%) 0% 30.2 270,619 Common Shares
James R. Empfield EVP, Drug Discovery Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.23 per share. 04 Mar 2022 695 11,805 (0%) 0% 30.2 21,010 Common Shares
Christopher John Kenney Chief Medical Officer Purchase of securities on an exchange or from another person at price $ 28.81 per share. 21 Jan 2022 700 700 (0%) 0% 28.8 20,167 Common Shares
Simon Pimstone Director Sale of securities on an exchange or to another person at price $ 31.33 per share. 15 Nov 2021 17,557 210,186 (0%) 0% 31.3 550,061 Common Shares
Christopher John Kenney Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Aug 2021 150,000 150,000 - - Stock Option (Right to Buy)
Patrick C. Machado Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Jun 2021 10,000 10,000 - - Stock Option (Right to Buy)
Mohammad Azab Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Jun 2021 10,000 10,000 - - Stock Option (Right to Buy)
Ian C. Mortimer Director, PRESIDENT & CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Jun 2021 125,000 125,000 - - Stock Option (Right to Buy)
Michael Hayden Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Jun 2021 10,000 10,000 - - Stock Option (Right to Buy)
Dawn A. Svoronos Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Jun 2021 10,000 10,000 - - Stock Option (Right to Buy)
Steven Gannon Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Jun 2021 10,000 10,000 - - Stock Option (Right to Buy)
Elizabeth A. Garofalo Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Jun 2021 20,000 20,000 - - Stock Option (Right to Buy)
Sherry Aulin Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Jun 2021 100,000 100,000 - - Stock Option (Right to Buy)
Robin Sherrington EVP, Strategy & Innovation Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. 28 May 2021 12,345 29,141 (0%) 0% 3.8 46,417 Common Shares
Robin Sherrington EVP, Strategy & Innovation Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.91 per share. 28 May 2021 2,024 27,117 (0%) 0% 18.9 38,274 Common Shares
Robin Sherrington EVP, Strategy & Innovation Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 28 May 2021 13,374 40,491 (0%) 0% 3.9 51,490 Common Shares
Robin Sherrington EVP, Strategy & Innovation Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.91 per share. 28 May 2021 2,192 38,299 (0%) 0% 18.9 41,451 Common Shares
Robin Sherrington EVP, Strategy & Innovation Sale of securities on an exchange or to another person at price $ 18.81 per share. 28 May 2021 3,155 35,144 (0%) 0% 18.8 59,346 Common Shares
Robin Sherrington EVP, Strategy & Innovation Sale of securities on an exchange or to another person at price $ 18.81 per share. 28 May 2021 2,912 32,232 (0%) 0% 18.8 54,775 Common Shares
Robin Sherrington EVP, Strategy & Innovation Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 28 May 2021 12,345 0 - - Stock Option (Right to Buy)
Robin Sherrington EVP, Strategy & Innovation Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 28 May 2021 13,374 0 - - Stock Option (Right to Buy)
Frank Holler Director Sale of securities on an exchange or to another person at price $ 18.68 per share. 27 May 2021 8,485 143,653 (0%) 0% 18.7 158,500 Common Shares
Frank Holler Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 27 May 2021 3,086 0 - - Stock Option (Right to Buy)
Frank Holler Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 27 May 2021 36,008 0 - - Stock Option (Right to Buy)
Frank Holler Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. 27 May 2021 3,086 125,127 (0%) 0% 3.8 11,603 Common Shares
Frank Holler Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.88 per share. 27 May 2021 507 124,620 (0%) 0% 18.9 9,572 Common Shares
Frank Holler Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. 27 May 2021 36,008 160,628 (0%) 0% 3.8 135,390 Common Shares
Frank Holler Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.88 per share. 27 May 2021 5,911 154,717 (0%) 0% 18.9 111,600 Common Shares
Frank Holler Director Sale of securities on an exchange or to another person at price $ 18.69 per share. 27 May 2021 2,579 152,138 (0%) 0% 18.7 48,202 Common Shares
Simon Pimstone Director, CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.17 per share. 24 May 2021 5,076 227,743 (0%) 0% 19.2 97,307 Common Shares
Simon Pimstone Director, CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 24 May 2021 22,633 0 - - Stock Option (Right to Buy)
Simon Pimstone Director, CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. 24 May 2021 22,633 232,819 (0%) 0% 3.8 85,100 Common Shares
Michael M. Tarnow Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.67 per share. 18 May 2021 5,144 77,942 (0%) 0% 3.7 18,878 Common Shares
Michael M. Tarnow Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 18 May 2021 5,144 0 - - Stock Option (Right to Buy)
Michael M. Tarnow Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 18 May 2021 1,028 0 - - Stock Option (Right to Buy)
Michael M. Tarnow Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 18 May 2021 2,057 0 - - Stock Option (Right to Buy)
Michael M. Tarnow Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.67 per share. 18 May 2021 1,028 72,798 (0%) 0% 3.7 3,773 Common Shares
Michael M. Tarnow Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.87 per share. 18 May 2021 2,057 71,770 (0%) 0% 3.9 7,961 Common Shares
Michael Hayden Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 18 May 2021 3,500 116,206 (0%) 0% 3.9 13,475 Common Shares
Michael Hayden Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 18 May 2021 3,500 0 - - Stock Option (Right to Buy)
Gary Patou Director 17 Mar 2021 100 100 (0%) 0% 19.5 1,949 Common Shares
Gary Patou Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Mar 2021 10,000 10,000 - - Stock Option (Right to Buy)
Ian C. Mortimer PRESIDENT & CFO Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Mar 2021 100,000 100,000 - - Stock Option (Right to Buy)
Simon Pimstone Director, CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Mar 2021 225,000 225,000 - - Stock Option (Right to Buy)
Robin Sherrington EVP, Strategy & Innovation Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Mar 2021 65,000 65,000 - - Stock Option (Right to Buy)
James R. Empfield EVP, Drug Discovery Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Mar 2021 65,000 65,000 - - Stock Option (Right to Buy)
Seggern Christopher Von Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Mar 2021 60,000 60,000 - - Stock Option (Right to Buy)
Michael Hayden Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 16 Feb 2021 5,144 0 - - Stock Option (Right to Buy)
Michael Hayden Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.68 per share. 16 Feb 2021 30,864 92,076 (0%) 0% 2.7 82,716 Common Shares
Michael Hayden Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.67 per share. 16 Feb 2021 10,288 61,212 (0%) 0% 3.7 37,757 Common Shares
Michael Hayden Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 16 Feb 2021 30,864 0 - - Stock Option (Right to Buy)
Michael Hayden Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 16 Feb 2021 10,288 0 - - Stock Option (Right to Buy)
Michael Hayden Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.68 per share. 16 Feb 2021 5,144 112,706 (0%) 0% 2.7 13,786 Common Shares
Mohammad Azab Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 15 Dec 2020 3,086 0 - - Stock Option (Right to Buy)
Mohammad Azab Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. 15 Dec 2020 3,086 63,733 (0%) 0% 3.8 11,603 Common Shares
Patrick C. Machado Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Nov 2020 20,000 20,000 - - Stock Option (Right to Buy)
Michael M. Tarnow Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. 28 Oct 2020 5,144 80,001 (0%) 0% 3.8 19,341 Common Shares
Michael M. Tarnow Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 28 Oct 2020 5,144 0 - - Stock Option (Right to Buy)
Michael M. Tarnow Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 28 Oct 2020 5,144 0 - - Stock Option (Right to Buy)
Michael M. Tarnow Director Gift of securities by or to the insider at price $ 0.00 per share. 28 Oct 2020 10,288 69,713 (0%) 0% 0 Common Shares
Michael M. Tarnow Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. 28 Oct 2020 5,144 74,857 (0%) 0% 3.8 19,341 Common Shares
Gary Patou Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 28 Oct 2020 2,057 0 - - Stock Option (Right to Buy)
Gary Patou Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. 28 Oct 2020 2,057 23,573 (0%) 0% 3.8 7,734 Common Shares
Simon Pimstone Director, CEO Other type of transaction at price $ 0.00 per share. 20 Aug 2020 45,000 210,186 (0%) 0% 0 Common Shares
Seggern Christopher Von Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Aug 2020 100,000 100,000 - - Stock Option (Right to Buy)
Michael M. Tarnow Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.52 per share. 09 Jun 2020 5,144 69,713 (0%) 0% 3.5 18,107 Common Shares
Michael M. Tarnow Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 09 Jun 2020 5,144 0 - - Stock Option (Right to Buy)
Mohammad Azab Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jun 2020 10,000 10,000 - - Stock Option (Right to Buy)
Michael M. Tarnow Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jun 2020 10,000 10,000 - - Stock Option (Right to Buy)
Gary Patou Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jun 2020 10,000 10,000 - - Stock Option (Right to Buy)
Michael Hayden Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jun 2020 10,000 10,000 - - Stock Option (Right to Buy)
Dawn Svoronos Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jun 2020 10,000 10,000 - - Stock Option (Right to Buy)
Robin Sherrington EVP, Strategy & Innovation Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.56 per share. 01 Jun 2020 8,230 18,426 (0%) 0% 3.6 29,299 Common Shares
Robin Sherrington EVP, Strategy & Innovation Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.70 per share. 01 Jun 2020 1,630 16,796 (0%) 0% 13.7 22,331 Common Shares
Robin Sherrington EVP, Strategy & Innovation Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 01 Jun 2020 8,230 0 - - Stock Option (Right to Buy)
Steven Gannon Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jun 2020 10,000 10,000 - - Stock Option (Right to Buy)
Clarissa Desjardins Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jun 2020 10,000 10,000 - - Stock Option (Right to Buy)
Frank Holler Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 29 May 2020 10,000 10,000 - - Stock Option (Right to Buy)
Frank Holler Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 29 May 2020 3,086 0 - - Stock Option (Right to Buy)
Frank Holler Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.56 per share. 29 May 2020 3,086 122,041 (0%) 0% 3.6 10,986 Common Shares
Simon Pimstone Director, CEO Sale of securities on an exchange or to another person at price $ 14.43 per share. 29 May 2020 3,000 255,186 (0%) 0% 14.4 43,290 Common Shares
Simon Pimstone Director, CEO Sale of securities on an exchange or to another person at price $ 13.99 per share. 29 May 2020 5,000 258,186 (0%) 0% 14.0 69,950 Common Shares
Simon Pimstone Director, CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.56 per share. 26 May 2020 6,172 264,294 (0%) 0% 3.6 21,972 Common Shares
Simon Pimstone Director, CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 26 May 2020 6,172 0 - - Stock Option (Right to Buy)
Simon Pimstone Director, CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.90 per share. 26 May 2020 1,108 263,186 (0%) 0% 14.9 16,509 Common Shares
Ian C. Mortimer PRESIDENT & CFO Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Mar 2020 145,000 145,000 - - Stock Option (Right to Buy)
Simon Pimstone Director, CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Mar 2020 280,000 280,000 - - Stock Option (Right to Buy)
Robin Sherrington EVP, Strategy & Innovation Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Mar 2020 65,000 65,000 - - Stock Option (Right to Buy)
James R. Empfield SVP, Drug Discovery Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Mar 2020 65,000 65,000 - - Stock Option (Right to Buy)
Ernesto Aycardi CMO Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Mar 2020 65,000 65,000 - - Stock Option (Right to Buy)
Clarissa Desjardins Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Jan 2020 25,000 25,000 - - Stock Option (Right to Buy)
Mohammad Azab None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 16 Dec 2019 3,086 0 - - Stock Option (Right to Buy)
Mohammad Azab None Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.56 per share. 16 Dec 2019 3,086 60,647 (0%) 0% 3.6 10,986 Common Shares
Gary Patou None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 04 Dec 2019 2,057 0 - - Stock Option (Right to Buy)
Gary Patou None Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.56 per share. 04 Dec 2019 2,057 21,516 (0%) 0% 3.6 7,323 Common Shares
Michael M. Tarnow None Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.56 per share. 21 Nov 2019 5,144 69,713 (0%) 0% 3.6 18,313 Common Shares
Michael M. Tarnow None Gift of securities by or to the insider at price $ 0.00 per share. 21 Nov 2019 5,144 64,569 (0%) 0% 0 Common Shares
Michael M. Tarnow None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 21 Nov 2019 2,057 0 - - Stock Option (Right to Buy)
Michael M. Tarnow None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 21 Nov 2019 5,144 0 - - Stock Option (Right to Buy)
Michael M. Tarnow None Gift of securities by or to the insider at price $ 0.00 per share. 21 Nov 2019 2,057 64,569 (0%) 0% 0 Common Shares
Michael M. Tarnow None Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.51 per share. 21 Nov 2019 2,057 66,626 (0%) 0% 3.5 7,220 Common Shares
Simon Pimstone Director, CEO Sale of securities on an exchange or to another person at price $ 9.51 per share. 20 Sep 2019 10,395 258,122 (0%) 0% 9.5 98,856 Common Shares
Frank Holler None Sale of securities on an exchange or to another person at price $ 9.27 per share. 19 Sep 2019 7,600 124,161 (0%) 0% 9.3 70,452 Common Shares
Frank Holler None Sale of securities on an exchange or to another person at price $ 9.39 per share. 19 Sep 2019 5,206 118,955 (0%) 0% 9.4 48,884 Common Shares
Michael M. Tarnow None Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Sep 2019 15,000 15,000 - - Stock Option (Right to Buy)
Gary Patou None Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Sep 2019 15,000 15,000 - - Stock Option (Right to Buy)
Richard H. Scheller None Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Sep 2019 15,000 15,000 - - Stock Option (Right to Buy)
Frank Holler None Sale of securities on an exchange or to another person at price $ 9.32 per share. 16 Sep 2019 5,069 136,129 (0%) 0% 9.3 47,243 Common Shares
Frank Holler None Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Sep 2019 15,000 15,000 - - Stock Option (Right to Buy)
Frank Holler None Sale of securities on an exchange or to another person at price $ 9.28 per share. 16 Sep 2019 4,368 131,761 (0%) 0% 9.3 40,535 Common Shares
Ian C. Mortimer PRESIDENT & CFO Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Sep 2019 135,000 135,000 - - Stock Option (Right to Buy)
Michael Hayden None Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Sep 2019 15,000 15,000 - - Stock Option (Right to Buy)
Dawn Svoronos None Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Sep 2019 15,000 15,000 - - Stock Option (Right to Buy)
Simon Pimstone Director, CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.70 per share. 16 Sep 2019 36,008 264,143 (0%) 0% 3.7 133,230 Common Shares
Simon Pimstone Director, CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.44 per share. 16 Sep 2019 10,769 253,374 (0%) 0% 9.4 101,659 Common Shares
Simon Pimstone Director, CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.07 per share. 16 Sep 2019 9,259 262,633 (0%) 0% 3.1 28,425 Common Shares
Simon Pimstone Director, CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.44 per share. 16 Sep 2019 2,769 259,864 (0%) 0% 9.4 26,139 Common Shares
Simon Pimstone Director, CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.38 per share. 16 Sep 2019 12,345 272,209 (0%) 0% 3.4 41,726 Common Shares
Simon Pimstone Director, CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.44 per share. 16 Sep 2019 3,692 268,517 (0%) 0% 9.4 34,852 Common Shares
Simon Pimstone Director, CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Sep 2019 280,000 280,000 - - Stock Option (Right to Buy)
Simon Pimstone Director, CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 16 Sep 2019 36,008 0 - - Stock Option (Right to Buy)
Simon Pimstone Director, CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 16 Sep 2019 9,259 0 - - Stock Option (Right to Buy)
Simon Pimstone Director, CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 16 Sep 2019 12,345 0 - - Stock Option (Right to Buy)
Robin Sherrington EVP, Strategy & Innovation Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Sep 2019 45,000 45,000 - - Stock Option (Right to Buy)
Steven Gannon None Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Sep 2019 15,000 15,000 - - Stock Option (Right to Buy)
James R. Empfield SVP, Drug Discovery Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Sep 2019 40,000 40,000 - - Stock Option (Right to Buy)
Ernesto Aycardi CMO Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Sep 2019 65,000 65,000 - - Stock Option (Right to Buy)
Mohammad Azab None Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Sep 2019 15,000 15,000 - - Stock Option (Right to Buy)
Mohammad Azab None Sale of securities on an exchange or to another person at price $ 9.30 per share. 13 Sep 2019 23 57,561 (0%) 0% 9.3 214 Common Shares
Frank Holler None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 12 Sep 2019 3,086 0 - - Stock Option (Right to Buy)
Frank Holler None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 12 Sep 2019 25,720 0 - - Stock Option (Right to Buy)
Frank Holler None Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.07 per share. 12 Sep 2019 3,086 124,193 (0%) 0% 3.1 9,474 Common Shares
Frank Holler None Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.38 per share. 12 Sep 2019 934 121,107 (0%) 0% 9.4 8,761 Common Shares
Frank Holler None Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.70 per share. 12 Sep 2019 3,086 122,041 (0%) 0% 3.7 11,418 Common Shares
Frank Holler None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 12 Sep 2019 3,086 0 - - Stock Option (Right to Buy)
Frank Holler None Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.38 per share. 12 Sep 2019 7,781 141,198 (0%) 0% 9.4 72,986 Common Shares
Frank Holler None Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.00 per share. 12 Sep 2019 25,720 148,979 (0%) 0% 3 77,160 Common Shares
Frank Holler None Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.38 per share. 12 Sep 2019 934 123,259 (0%) 0% 9.4 8,761 Common Shares
Robin Sherrington EVP, Strategy & Innovation Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.38 per share. 12 Sep 2019 1,868 10,196 (0%) 0% 9.4 17,522 Common Shares
Robin Sherrington EVP, Strategy & Innovation Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.07 per share. 12 Sep 2019 6,172 12,064 (0%) 0% 3.1 18,948 Common Shares
Robin Sherrington EVP, Strategy & Innovation Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 12 Sep 2019 6,172 0 - - Stock Option (Right to Buy)
Michael M. Tarnow None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 21 May 2019 2,057 0 - - Stock Option (Right to Buy)
Michael M. Tarnow None Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.21 per share. 21 May 2019 2,057 64,569 (0%) 0% 3.2 6,603 Common Shares
Michael Hayden None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Mar 2019 20,576 0 - - Stock Option (Right to Buy)
Michael Hayden None Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.38 per share. 19 Mar 2019 20,576 50,924 (0%) 0% 3.4 69,547 Common Shares
Michael Hayden None Gift of securities by or to the insider at price $ 0.00 per share. 11 Mar 2019 24,045 107,562 (0%) 0% 0 Common Shares
Michael Hayden None Gift of securities by or to the insider at price $ 0.00 per share. 11 Mar 2019 17,337 114,403 (0%) 0% 0 Common Shares
Michael M. Tarnow None Gift of securities by or to the insider at price $ 0.00 per share. 21 Dec 2018 5,000 62,512 (0%) 0% 0 Common Shares
Gary Patou None Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.07 per share. 14 Dec 2018 2,057 19,459 (0%) 0% 3.1 6,315 Common Shares
Gary Patou None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Dec 2018 2,057 0 - - Stock Option (Right to Buy)
Charles J. Cohen VP, Biology Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.07 per share. 11 Dec 2018 4,115 8,194 (0%) 0% 3.1 12,633 Common Shares
Charles J. Cohen VP, Biology Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.00 per share. 11 Dec 2018 1,644 6,550 (0%) 0% 7 11,508 Common Shares
Charles J. Cohen VP, Biology Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 11 Dec 2018 4,115 0 - - Stock Option (Right to Buy)
Mohammad Azab None Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.07 per share. 06 Dec 2018 3,086 57,584 (0%) 0% 3.1 9,474 Common Shares
Mohammad Azab None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 06 Dec 2018 3,086 0 - - Stock Option (Right to Buy)
Mohammad Azab None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 21 Jun 2018 10,288 0 - - Stock Option (Right to Buy)
Mohammad Azab None Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.70 per share. 21 Jun 2018 10,288 54,498 (0%) 0% 3.7 38,066 Common Shares
Michael M. Tarnow None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 21 Jun 2018 2,057 0 - - Stock Option (Right to Buy)
Michael M. Tarnow None Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.07 per share. 21 Jun 2018 5,144 67,512 (0%) 0% 3.1 15,792 Common Shares
Michael M. Tarnow None Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.66 per share. 21 Jun 2018 2,057 62,368 (0%) 0% 3.7 7,529 Common Shares
Michael M. Tarnow None Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.70 per share. 21 Jun 2018 5,144 60,311 (0%) 0% 3.7 19,033 Common Shares
Michael M. Tarnow None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 21 Jun 2018 5,144 0 - - Stock Option (Right to Buy)
Michael M. Tarnow None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 21 Jun 2018 5,144 0 - - Stock Option (Right to Buy)
Gary Patou None Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.70 per share. 14 Jun 2018 8,230 20,258 (0%) 0% 3.7 30,451 Common Shares
Gary Patou None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2018 8,230 0 - - Stock Option (Right to Buy)
Gary Patou None Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.30 per share. 14 Jun 2018 2,856 17,402 (0%) 0% 8.3 23,705 Common Shares
Mohammad Azab None Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Jun 2018 15,000 15,000 - - Stock Option (Right to Buy)
Michael M. Tarnow None Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Jun 2018 15,000 15,000 - - Stock Option (Right to Buy)
Gary Patou None Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Jun 2018 15,000 15,000 - - Stock Option (Right to Buy)
Richard H. Scheller None Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Jun 2018 15,000 15,000 - - Stock Option (Right to Buy)
Frank Holler None Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Jun 2018 15,000 15,000 - - Stock Option (Right to Buy)
Michael Hayden None Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Jun 2018 15,000 15,000 - - Stock Option (Right to Buy)
Dawn Svoronos None Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Jun 2018 15,000 15,000 - - Stock Option (Right to Buy)
Steven Gannon None Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Jun 2018 15,000 15,000 - - Stock Option (Right to Buy)
Ernesto Aycardi Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Mar 2018 50,000 50,000 - - Stock Option (Right to Buy)
Robin Sherrington EVP Bus. & Corp. Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.77 per share. 15 Mar 2018 3,086 7,820 (0%) 0% 3.8 11,634 Common Shares
Robin Sherrington EVP Bus. & Corp. Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 15 Mar 2018 3,086 0 - - Stock Option (Right to Buy)
Robin Sherrington EVP Bus. & Corp. Development Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.62 per share. 15 Mar 2018 1,928 5,892 (0%) 0% 4.6 8,917 Common Shares
Frank Holler None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Mar 2018 3,086 0 - - Stock Option (Right to Buy)
Frank Holler None Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.77 per share. 14 Mar 2018 3,086 118,955 (0%) 0% 3.8 11,634 Common Shares
Ian C. Mortimer PRESIDENT & CFO Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Mar 2018 105,000 105,000 - - Stock Option (Right to Buy)
Simon Pimstone Director, CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.77 per share. 12 Mar 2018 10,288 228,135 (1%) 0% 3.8 38,786 Common Shares
Simon Pimstone Director, CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 12 Mar 2018 10,288 0 - - Stock Option (Right to Buy)
Simon Pimstone Director, CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Mar 2018 140,000 140,000 - - Stock Option (Right to Buy)
Charles J. Cohen VP, Biology Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Mar 2018 40,000 40,000 - - Stock Option (Right to Buy)
Robin Sherrington EVP Bus. & Corp. Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Mar 2018 55,000 55,000 - - Stock Option (Right to Buy)
James R. Empfield SVP, Drug Discovery Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Mar 2018 45,000 45,000 - - Stock Option (Right to Buy)
Michael Hayden None Gift of securities by or to the insider at price $ 0.00 per share. 22 Feb 2018 21,180 97,066 (0%) 0% 0 Common Shares
Michael Hayden None Gift of securities by or to the insider at price $ 0.00 per share. 22 Feb 2018 29,580 131,607 (0%) 0% 0 Common Shares
Charles J. Cohen VP, Biology Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.71 per share. 12 Feb 2018 26,748 26,748 (0%) 0% 3.7 99,235 Common Shares
Charles J. Cohen VP, Biology Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.50 per share. 12 Feb 2018 22,669 4,079 (0%) 0% 3.5 79,342 Common Shares
Charles J. Cohen VP, Biology Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 12 Feb 2018 26,748 0 - - Stock Option (Right to Buy)
Mohammad Azab None Purchase of securities on an exchange or from another person at price $ 2.22 per share. 15 Nov 2017 15,000 44,210 (0%) 0% 2.2 33,281 Common Shares
Ian C. Mortimer CFO & COO Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Oct 2017 25,000 25,000 - - Stock Option (Right to Buy)
Simon Pimstone Director, President & CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Oct 2017 11,000 11,000 - - Stock Option (Right to Buy)
Charles J. Cohen VP, Biology Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Oct 2017 11,000 11,000 - - Stock Option (Right to Buy)
Y. Paul Goldberg SVP, Clinical Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Oct 2017 11,000 11,000 - - Stock Option (Right to Buy)
Robin Sherrington SVP Bus. & Corp. Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Oct 2017 11,000 11,000 - - Stock Option (Right to Buy)
James R. Empfield SVP, Drug Discovery Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Oct 2017 20,000 20,000 - - Stock Option (Right to Buy)
Mohammad Azab None Purchase of securities on an exchange or from another person at price $ 2.95 per share. 21 Sep 2017 8,000 29,210 (0%) 0% 3.0 23,600 Common Shares
Mohammad Azab None Purchase of securities on an exchange or from another person at price $ 2.95 per share. 21 Sep 2017 2,000 21,210 (0%) 0% 3.0 5,900 Common Shares
Raymond J. Winquist Head, Translational Research Purchase of securities on an exchange or from another person at price $ 3.00 per share. 18 Aug 2017 1,000 1,000 (0%) 0% 3.0 2,995 Common Shares
Mohammad Azab None Purchase of securities on an exchange or from another person at price $ 2.65 per share. 17 Aug 2017 23 12,898 (0%) 0% 2.7 61 Common Shares
Mohammad Azab None Purchase of securities on an exchange or from another person at price $ 2.90 per share. 17 Aug 2017 6,312 19,210 (0%) 0% 2.9 18,302 Common Shares
James R. Empfield SVP, Drug Discovery Purchase of securities on an exchange or from another person at price $ 2.48 per share. 15 Aug 2017 10,000 10,000 (0%) 0% 2.5 24,824 Common Shares
Michael Hayden None Purchase of securities on an exchange or from another person at price $ 2.75 per share. 14 Aug 2017 15,000 161,187 (0%) 0% 2.7 41,247 Common Shares
Dawn Svoronos None Purchase of securities on an exchange or from another person at price $ 2.82 per share. 14 Aug 2017 50,000 50,000 (0%) 0% 2.8 140,770 Common Shares
Steven Gannon None Purchase of securities on an exchange or from another person at price $ 2.82 per share. 11 Aug 2017 15,000 15,000 (0%) 0% 2.8 42,267 Common Shares
Gary Patou None Purchase of securities on an exchange or from another person at price $ 2.78 per share. 10 Aug 2017 7,500 12,500 (0%) 0% 2.8 20,836 Common Stock
Richard H. Scheller None Purchase of securities on an exchange or from another person at price $ 2.85 per share. 10 Aug 2017 7,000 7,000 (0%) 0% 2.9 19,950 Common Shares
Ian C. Mortimer CFO & COO Purchase of securities on an exchange or from another person at price $ 2.90 per share. 10 Aug 2017 10,000 14,300 (0%) 0% 2.9 29,000 Common Stock
Ian C. Mortimer CFO & COO Purchase of securities on an exchange or from another person at price $ 2.84 per share. 10 Aug 2017 5,000 6,000 (0%) 0% 2.8 14,225 Common Stock
Simon Pimstone Director, President & CEO Purchase of securities on an exchange or from another person at price $ 2.90 per share. 10 Aug 2017 6,000 217,847 (1%) 0% 2.9 17,400 Common Shares
Gary Patou None Purchase of securities on an exchange or from another person at price $ 3.00 per share. 08 Aug 2017 5,000 5,000 (0%) 0% 3.0 15,003 Common Stock
Michael M. Tarnow None Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.51 per share. 19 Jun 2017 1,028 56,195 (0%) 0% 3.5 3,608 Common Shares
Michael M. Tarnow None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Jun 2017 1,028 0 - - Stock Option (Right to Buy)
Michael M. Tarnow None Gift of securities by or to the insider at price $ 0.00 per share. 19 Jun 2017 1,028 55,167 (0%) 0% 0 Common Shares
Mohammad Azab None Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jun 2017 3,500 3,500 - - Stock Option (Right to Buy)
Michael M. Tarnow None Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jun 2017 3,500 3,500 - - Stock Option (Right to Buy)
Michael M. Tarnow None Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jun 2017 1,250 1,250 - - Stock Option (Right to Buy)
Gary Patou None Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jun 2017 3,500 3,500 - - Stock Option (Right to Buy)
Richard H. Scheller None Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jun 2017 3,500 3,500 - - Stock Option (Right to Buy)
Frank Holler None Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jun 2017 3,500 3,500 - - Stock Option (Right to Buy)
Michael Hayden None Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jun 2017 3,500 3,500 - - Stock Option (Right to Buy)
Dawn Svoronos None Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jun 2017 3,500 3,500 - - Stock Option (Right to Buy)
Steven Gannon None Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jun 2017 3,500 3,500 - - Stock Option (Right to Buy)
Robin Sherrington SVP Bus. & Corp. Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.21 per share. 12 May 2017 2,057 6,079 (0%) 0% 3.2 6,603 Common Shares
Robin Sherrington SVP Bus. & Corp. Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 12 May 2017 2,057 0 - - Stock Option (Right to Buy)
Robin Sherrington SVP Bus. & Corp. Development Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.18 per share. 12 May 2017 1,345 4,734 (0%) 0% 4.2 5,622 Common Shares
Michael Hayden None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Mar 2017 18,004 0 - - Stock Option (Right to Buy)
Michael Hayden None Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.56 per share. 14 Mar 2017 3,086 30,348 (0%) 0% 3.6 10,986 Common Shares
Michael Hayden None Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.07 per share. 14 Mar 2017 4,629 27,262 (0%) 0% 3.1 14,211 Common Shares
Michael Hayden None Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.77 per share. 14 Mar 2017 4,115 22,633 (0%) 0% 3.8 15,514 Common Shares
Michael Hayden None Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.67 per share. 14 Mar 2017 5,144 146,187 (0%) 0% 3.7 18,878 Common Shares
Michael Hayden None Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. 14 Mar 2017 25,720 141,043 (0%) 0% 3.8 96,707 Common Shares
Michael Hayden None Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.70 per share. 14 Mar 2017 18,004 115,323 (0%) 0% 3.7 66,615 Common Shares
Michael Hayden None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Mar 2017 5,144 0 - - Stock Option (Right to Buy)
Michael Hayden None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Mar 2017 25,720 0 - - Stock Option (Right to Buy)
Michael Hayden None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Mar 2017 3,086 0 - - Stock Option (Right to Buy)
Michael Hayden None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Mar 2017 4,629 0 - - Stock Option (Right to Buy)
Michael Hayden None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Mar 2017 4,115 0 - - Stock Option (Right to Buy)
Ian C. Mortimer CFO & COO Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Mar 2017 75,000 75,000 - - Stock Option (Right to Buy)
Simon Pimstone Director, President & CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Mar 2017 140,000 140,000 - - Stock Option (Right to Buy)
Charles J. Cohen VP, Biology Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Mar 2017 20,000 20,000 - - Stock Option (Right to Buy)
Y. Paul Goldberg SVP, Clinical Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Mar 2017 27,500 27,500 - - Stock Option (Right to Buy)
Robin Sherrington SVP Bus. & Corp. Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Mar 2017 27,500 27,500 - - Stock Option (Right to Buy)
James R. Empfield SVP, Drug Discovery Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Mar 2017 27,500 27,500 - - Stock Option (Right to Buy)
Raymond J. Winquist Head, Translational Research Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Mar 2017 20,000 20,000 - - Stock Option (Right to Buy)
Michael M. Tarnow None Gift of securities by or to the insider at price $ 0.00 per share. 26 Jan 2017 7,201 55,167 (0%) 0% 0 Common Shares
Frank Holler None Sale of securities on an exchange or to another person at price $ 0.00 per share. 15 Dec 2016 30,000 115,869 - - Common Shares
Michael M. Tarnow None Gift of securities by or to the insider at price $ 0.00 per share. 12 Dec 2016 7,202 62,368 - - Common Shares
Michael M. Tarnow None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 12 Dec 2016 14,403 69,570 - - Common Shares
Michael M. Tarnow None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 12 Dec 2016 14,403 0 - - Stock Option (Right to Buy)
Gary Patou None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 06 Dec 2016 12,345 16,431 - - Common Shares
Gary Patou None Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. 06 Dec 2016 4,403 12,028 - - Common Shares
Gary Patou None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 06 Dec 2016 12,345 0 - - Stock Option (Right to Buy)
Mohammad Azab None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 01 Dec 2016 12,345 17,283 - - Common Shares
Mohammad Azab None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 01 Dec 2016 12,345 0 - - Stock Option (Right to Buy)
Mohammad Azab None Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. 01 Dec 2016 4,408 12,875 - - Common Shares
Dawn Svoronos None Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Sep 2016 5,144 5,144 - - Stock Option (Right to Buy)
Frank Holler None Sale of securities on an exchange or to another person at price $ 0.00 per share. 19 Aug 2016 11,938 145,869 - - Common Shares
Frank Holler None Sale of securities on an exchange or to another person at price $ 0.00 per share. 16 Aug 2016 9,599 157,807 - - Common Shares
Frank Holler None Sale of securities on an exchange or to another person at price $ 0.00 per share. 16 Aug 2016 1,600 167,406 - - Common Shares
Frank Holler None Sale of securities on an exchange or to another person at price $ 0.00 per share. 16 Aug 2016 6,863 169,006 - - Common Shares
Simon Pimstone Director, President & CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 29 Jul 2016 12,345 0 - - Stock Option (Right to Buy)
Simon Pimstone Director, President & CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 29 Jul 2016 12,345 216,550 - - Common Shares
Simon Pimstone Director, President & CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. 29 Jul 2016 4,703 211,847 - - Common Shares
Ian C. Mortimer CFO & COO Purchase of securities on an exchange or from another person at price $ 0.00 per share. 24 Jun 2016 2,000 3,000 - - Common Stock
Ian C. Mortimer CFO & COO Purchase of securities on an exchange or from another person at price $ 0.00 per share. 24 Jun 2016 1,000 1,000 - - Common Stock
Ian C. Mortimer CFO & COO Purchase of securities on an exchange or from another person at price $ 0.00 per share. 24 Jun 2016 1,300 4,300 - - Common Stock
Ian C. Mortimer CFO & COO Purchase of securities on an exchange or from another person at price $ 0.00 per share. 24 Jun 2016 1,000 1,000 - - Common Stock
Michael M. Tarnow None Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2016 3,500 3,500 - - Stock Option (Right to Buy)
Michael M. Tarnow None Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2016 1,250 1,250 - - Stock Option (Right to Buy)
Richard H. Scheller None Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2016 3,500 3,500 - - Stock Option (Right to Buy)
Mohammad Azab None Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2016 3,500 3,500 - - Stock Option (Right to Buy)
Gary Patou None Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2016 3,500 3,500 - - Stock Option (Right to Buy)
Frank Holler None Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2016 3,500 3,500 - - Stock Option (Right to Buy)
Michael Hayden None Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2016 3,500 3,500 - - Stock Option (Right to Buy)
Steven Gannon None Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2016 3,500 3,500 - - Stock Option (Right to Buy)
Michael Hayden None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 25 May 2016 8,230 0 - - Stock Option (Right to Buy)
Michael Hayden None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 25 May 2016 8,230 18,518 - - Common Shares
Michael M. Tarnow None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 28 Apr 2016 1,543 56,710 - - Common Shares
Michael M. Tarnow None Gift of securities by or to the insider at price $ 0.00 per share. 28 Apr 2016 1,543 55,167 - - Common Shares
Michael M. Tarnow None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 28 Apr 2016 1,543 0 - - Stock Option (Right to Buy)
Raymond J. Winquist Head, Translational Research Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Apr 2016 35,000 35,000 - - Stock Option (Right to Buy)
Ian C. Mortimer CFO & COO Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Mar 2016 40,000 40,000 - - Stock Option (Right to Buy)
Simon Pimstone Director, President & CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Mar 2016 50,000 50,000 - - Stock Option (Right to Buy)
Charles J. Cohen VP, Biology Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Mar 2016 25,000 25,000 - - Stock Option (Right to Buy)
Y. Paul Goldberg VP, Clinical Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Mar 2016 20,000 20,000 - - Stock Option (Right to Buy)
Robin Sherrington SVP Bus. & Corp. Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Mar 2016 20,000 20,000 - - Stock Option (Right to Buy)
James R. Empfield SVP, Drug Discovery Grant, award, or other acquisition of securities at price $ 0.00 per share. 08 Feb 2016 40,000 40,000 - - Stock Option (Right to Buy)
Ian C. Mortimer CFO & COO Grant, award, or other acquisition of securities at price $ 0.00 per share. 18 Dec 2015 25,000 25,000 - - Stock Option (Right to Buy)
Simon Pimstone Director, President & CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 18 Dec 2015 40,000 40,000 - - Stock Option (Right to Buy)
Charles J. Cohen VP, Biology Grant, award, or other acquisition of securities at price $ 0.00 per share. 18 Dec 2015 15,000 15,000 - - Stock Option (Right to Buy)
Y. Paul Goldberg VP of Clinical Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 18 Dec 2015 15,000 15,000 - - Stock Option (Right to Buy)
Robin Sherrington SVP Bus. & Corp. Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 18 Dec 2015 15,000 15,000 - - Stock Option (Right to Buy)
Robin Sherrington SVP Bus. & Corp. Development Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. 16 Dec 2015 229 4,022 - - Common Shares
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures
Screeners based on Insider Trading and SAST parameters